<DOC>
	<DOCNO>NCT01290887</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety reslizumab dosage 3.0 mg/kg every 4 week approximately 24 month pediatric adult patient eosinophilic asthma assess adverse event , physical examination finding , vital sign measurement , concomitant medication usage throughout study ( every 4 week ) , clinical laboratory test result , measurement antidrug antibody .</brief_summary>
	<brief_title>Open-Label Extension Study Evaluate Long-Term Safety Efficacy Reslizumab ( 3.0 mg/kg ) Treatment Patients ( 12 Through 75 Years Age ) With Eosinophilic Asthma</brief_title>
	<detailed_description>Study patient deem eligible base activity precede Teva sponsor double blind study reslizumab eosinophilic asthma . Specifically , per inclusion criterion c , patient must either complete treatment previous Teva-sponsored study receive least 2 dos study drug treatment pulmonary function study . Eligible patient could enroll study completion end treatment visit Teva sponsor , randomize , placebo control , double blind study reslizumab eosinophilic asthma , serve screening/baseline visit participation open label extension study . The use systemic corticosteroid asthma previous Teva sponsor double blind study reslizumab exclude patient study . The previous Teva study C38072/3081 ( NCT01270464 ) , C38072/3082 ( NCT01287039 ) , C38072/3083 ( NCT01285323 ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<criteria>Written inform consent obtain . Patient must complete treatment previous Cephalonsponsored doubleblind asthma exacerbation study receive least 2 dos study drug treatment pulmonary function study . The patient must willing able comply study restriction remain clinic require duration study period , willing return clinic followup evaluation specify protocol . criterion may apply ; please contact investigator information . The patient clinically meaningful comorbidity would interfere study schedule procedure , compromise patient 's safety . The patient another confound underlying lung disorder ( eg , chronic obstructive pulmonary disease , pulmonary fibrosis , lung cancer ) . The patient current smoker . The patient expect poorly compliant study drug administration , study procedure , visit . The patient aggravating factor inadequately control ( e.g. , gastroesophageal reflux disease [ GERD ] ) . Female patient pregnant , nursing , , childbearing potential use medically accept , effective method birth control ( eg , spermicide , abstinence , intrauterine device [ IUD ] , steroidal contraceptive [ oral , transdermal , implanted , injected ] conjunction barrier method ) exclude study . The patient current infection disease may preclude assessment asthma . criterion may apply ; please contact investigator information .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>